Skip to main content

Sustained Therapeutics

Monday, February 26, 2024
Pain Management
Sustained Therapeutics is a clinical stage company utilizing advanced clinical and research expertise to develop a patented novel locally injected sustained-release drug delivery platform. This platform can deliver multiple different drugs. Our first product is a non-opioid therapeutic with the potential to provide effective, long-lasting solutions for managing both acute and chronic pain. Designed to relieve pain in a highly controlled way over longer periods with fewer side effects than current standard of care, it offers up to four weeks of pain relief from a single injection. In addition it is non-addictive, unlike opioid drugs. Sustained Therapeutics has completed a successful Phase I trial and has two Phase II trials underway, one in post-operative pain and the other in chronic pain. We anticipate completing these trials in mid-2024. A Phase II study of our second product, an oncology drug with an orphan indication, has received regulatory approval and will commence soon.
William Annett, CEO - Sustained Theraeputics


British Columbia




CEO/Top Company Official

William Annett

Lead Product in Development

ST-01 for acute post-operative and chronic pain

Development Phase of Primary Product

Phase II

Number Of Unlicensed Products


Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.